Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) Research & Development (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Research & Development data on record, last reported at $8.2 million in Q4 2025.

  • For Q4 2025, Research & Development rose 140.67% year-over-year to $8.2 million; the TTM value through Dec 2025 reached $17.7 million, up 42.15%, while the annual FY2025 figure was $17.7 million, 42.15% up from the prior year.
  • Research & Development reached $8.2 million in Q4 2025 per LCTX's latest filing, up from $3.3 million in the prior quarter.
  • Across five years, Research & Development topped out at $8.2 million in Q4 2025 and bottomed at $2.9 million in Q2 2024.
  • Average Research & Development over 5 years is $3.7 million, with a median of $3.4 million recorded in 2021.
  • Peak YoY movement for Research & Development: dropped 28.08% in 2024, then soared 140.67% in 2025.
  • A 5-year view of Research & Development shows it stood at $3.4 million in 2021, then increased by 20.92% to $4.1 million in 2022, then decreased by 4.82% to $3.9 million in 2023, then dropped by 12.37% to $3.4 million in 2024, then skyrocketed by 140.67% to $8.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $8.2 million in Q4 2025, $3.3 million in Q3 2025, and $3.1 million in Q2 2025.